Online Resource 3

Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study

*International Journal of Clinical Oncology*

Ryuji Yasumatsu, Yasushi Shimizu, Nobuhiro Hanai, Shin Kariya, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Mizuo Ando, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Syuji Yonekura, Takahiro Asakage, Takahiro Nekado, Takayuki Yamada, Akihiro Homma

**Corresponding Author:** Akihiro Homma, E-mail: ak-homma@med.hokudai.ac.jp
Overall survival among patients according to histology status

| Histology | N   | Median OS (95% CI, (months)) | 6-month OS rate (%) | 12-month OS rate (%) | 18-month OS rate (%) | 24-month OS rate (%) |
|-----------|-----|------------------------------|---------------------|----------------------|----------------------|----------------------|
| Non-SCC   | 29  | 15.1 (4.5–NR)                | 64.9                | 54.1                 | 43                   | 35.1                 |
| SCC       | 217 | 9.1 (7.4–10.4)               | 62.8                | 40.8                 | 32.3                 | 28.4                 |

NR not reached, OS overall survival, SCC squamous cell carcinoma, *log-rank test